{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:29:55Z","timestamp":1791919795316,"version":"4.3.4"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The recent viral pandemic poses a unique challenge for healthcare providers. Despite the remarkable progress, the number of novel antiviral agents in the pipeline is woefully inadequate against the evolving virulence and drug resistance of current viruses. This highlights the urgent need for new and improved vaccines, diagnostics and therapeutic agents to obviate the viral pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Benzothiazole plays a pivotal role in the design and development of antiviral drugs. This is evident from the fact that it comprises many clinically useful agents. The current review is aimed to provide an insight into the recent development of benzothiazole-based antiviral agents, with a special focus on their structure-activity relationships and lead optimisation. One hundred and five articles were initially identified, and from these studies, 64 potential novel lead molecules and main findings were highlighted in this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We hope this review will provide a logical perspective on the importance of improving the future designs of novel broad-spectrum benzothiazole-based antiviral agents to be used against emerging viral diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jphp.13331","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T03:36:47Z","timestamp":1595561807000},"page":"1459-1480","source":"Crossref","is-referenced-by-count":103,"title":["Benzothiazoles as potential antiviral agents"],"prefix":"10.1093","volume":"72","author":[{"given":"Yahya I","family":"Asiri","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Pharmacy, King Khalid University , Abha,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrhman","family":"Alsayari","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, College of Pharmacy, King Khalid University , Abha,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullatif B","family":"Muhsinah","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, College of Pharmacy, King Khalid University , Abha,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia N","family":"Mabkhot","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University , Abha,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-5379","authenticated-orcid":false,"given":"Mohd Z","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University , Abha,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,1]]},"reference":[{"key":"2024103012371917600_jphp13331-cit-0001","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41579-019-0222-5","article-title":"Scientists\u2019 warning to humanity: microorganisms and climate change","volume":"17","author":"Cavicchioli","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2024103012371917600_jphp13331-cit-0002","first-page":"1314","article-title":"Do we need a Global Virome Project?","volume":"7","author":"Jonas","year":"2019","journal-title":"The Lancet"},{"key":"2024103012371917600_jphp13331-cit-0003","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2471\/BLT.17.205005","article-title":"Building a global atlas of zoonotic viruses","volume":"96","author":"Carroll","year":"2018","journal-title":"Bull World Health Organ"},{"key":"2024103012371917600_jphp13331-cit-0004","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3201\/eid2505.181247","article-title":"Increase in Lassa fever cases in Nigeria, January\u2013March 2018","volume":"25","author":"Ilori","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2024103012371917600_jphp13331-cit-0005","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(18)31252-2","article-title":"Nipah virus outbreak in India","volume":"391","author":"Patralekha","year":"2018","journal-title":"Lancet"},{"key":"2024103012371917600_jphp13331-cit-0006","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bjid.2017.02.004","article-title":"Yellow fever outbreak in Brazil, 2017","volume":"21","author":"Goldani","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"2024103012371917600_jphp13331-cit-0007","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"2024103012371917600_jphp13331-cit-0008","first-page":"3025","article-title":"Zika virus: a review of literature","volume":"10","author":"Agumadu","year":"2018","journal-title":"Cureus"},{"key":"2024103012371917600_jphp13331-cit-0009","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1016\/S2214-109X(20)30114-5","article-title":"Use of antiviral drugs to reduce COVID-19 transmission","volume":"8","author":"Mitj\u00e0","year":"2020","journal-title":"Lancet Global Health"},{"key":"2024103012371917600_jphp13331-cit-0010","article-title":"Structure and classification of viruses","volume-title":"The Medical Microbiology","author":"Gelderblom","year":"1996","edition":"4th edn"},{"key":"2024103012371917600_jphp13331-cit-0011","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/emi.2012.47","article-title":"Emerging virus diseases: can we ever expect the unexpected?","volume":"1","author":"Howard","year":"2012","journal-title":"Emerg Microbes Infect"},{"key":"2024103012371917600_jphp13331-cit-0012","first-page":"1","article-title":"Cell culture, cytopathic effect and immunofluorescence diagnosis of viral infection","volume":"2","author":"Dilnessa","year":"2017","journal-title":"J Microb Mod Tech"},{"key":"2024103012371917600_jphp13331-cit-0013","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.apsb.2014.06.005","article-title":"A cell-based high-throughput approach to identify inhibitors of influenza A virus","volume":"4","author":"Gao","year":"2014","journal-title":"Acta Pharm Sin B"},{"key":"2024103012371917600_jphp13331-cit-0014","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","article-title":"Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond","volume":"155","author":"Chaudhuri","year":"2018","journal-title":"Antivir Res"},{"key":"2024103012371917600_jphp13331-cit-0015","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1517\/14656566.5.12.2567","article-title":"Docosanol: a topical antiviral for herpes labialis","volume":"5","author":"Leung","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"2024103012371917600_jphp13331-cit-0016","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/fvl.14.70","article-title":"Novel drugs targeting Toll-like receptors for antiviral therapy","volume":"9","author":"Patel","year":"2014","journal-title":"Future Virol"},{"key":"2024103012371917600_jphp13331-cit-0017","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/13543776.2017.1280463","article-title":"Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002\u20132016)","volume":"27","author":"Cuny","year":"2017","journal-title":"Exp Opin Ther Pat"},{"key":"2024103012371917600_jphp13331-cit-0018","first-page":"3","article-title":"C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection","volume":"2","author":"Barmania","year":"2013","journal-title":"Appl Transl Genom"},{"key":"2024103012371917600_jphp13331-cit-0019","doi-asserted-by":"crossref","first-page":"202","DOI":"10.12688\/f1000research.7665.1","article-title":"Current landscape of antiviral drug discovery","volume":"5","author":"Blair","year":"2016","journal-title":"F1000Res"},{"key":"2024103012371917600_jphp13331-cit-0020","first-page":"25","volume-title":"Handb Exp Pharmacol","author":"Schinazi","year":"2009"},{"key":"2024103012371917600_jphp13331-cit-0021","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejmech.2016.07.056","article-title":"Therapeutic potential of coumarins as antiviral agents","volume":"123","author":"Hassan","year":"2016","journal-title":"Eur J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0022","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ddtec.2012.07.009","article-title":"In silico virtual screening approaches for anti-viral drug discovery","volume":"9","author":"Murgueitio","year":"2012","journal-title":"Drug Discov Today Technol"},{"key":"2024103012371917600_jphp13331-cit-0023","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.apsb.2017.04.009","article-title":"3,5-Bis(arylidene)-4-piperidones as potential dengue protease inhibitors","volume":"7","author":"Osman","year":"2017","journal-title":"Acta Pharm Sin B"},{"key":"2024103012371917600_jphp13331-cit-0024","first-page":"299","article-title":"Epidemiology of dengue: past, present and future prospects","volume":"5","author":"Murray","year":"2013","journal-title":"Clin Epidemiol"},{"key":"2024103012371917600_jphp13331-cit-0025","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiw423","article-title":"Current status of dengue therapeutics research and development","volume":"215","author":"Low","year":"2017","journal-title":"J Infect Dis"},{"key":"2024103012371917600_jphp13331-cit-0026","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.antiviral.2012.10.009","article-title":"Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro","volume":"97","author":"Lai","year":"2013","journal-title":"Antivir Res"},{"key":"2024103012371917600_jphp13331-cit-0027","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/AAC.03543-14","article-title":"Novel dengue virus NS2B\/NS3 protease inhibitors","volume":"59","author":"Wu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012371917600_jphp13331-cit-0028","doi-asserted-by":"crossref","first-page":"10278","DOI":"10.1128\/JVI.79.16.10278-10288.2005","article-title":"Structure of the dengue virus helicase\/nucleoside triphosphatase catalytic domain at a resolution of 2.4 A","volume":"79","author":"Xu","year":"2005","journal-title":"J Virol"},{"key":"2024103012371917600_jphp13331-cit-0029","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/id5000458","article-title":"Benzothiazole and pyrrolone flavivirus inhibitors targeting the viral helicase","volume":"1","author":"Sweeney","year":"2015","journal-title":"ACS Infect Dis"},{"key":"2024103012371917600_jphp13331-cit-0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fchem.2017.00088","article-title":"Targeting dengue virus NS-3 helicase by ligand based pharmacophore modeling and structure based virtual screening","volume":"5","author":"Halim","year":"2017","journal-title":"Front Chem"},{"key":"2024103012371917600_jphp13331-cit-0031","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.antiviral.2016.09.007","article-title":"Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor","volume":"134","author":"Tarantino","year":"2016","journal-title":"Antivir Res"},{"key":"2024103012371917600_jphp13331-cit-0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2019.03.004","article-title":"Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions","volume":"167","author":"Cannalire","year":"2019","journal-title":"Antivir Res"},{"issue":"5","key":"2024103012371917600_jphp13331-cit-0033","first-page":"541","article-title":"Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges","volume":"31","author":"Shahnazarian","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2024103012371917600_jphp13331-cit-0034","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"2024103012371917600_jphp13331-cit-0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2424","article-title":"The design of drugs for HIV and HCV","volume":"6","author":"De Clercq","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012371917600_jphp13331-cit-0036","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40264-016-0420-2","article-title":"Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and\/or renal impairment","volume":"39","author":"Smolders","year":"2016","journal-title":"Drug Saf"},{"key":"2024103012371917600_jphp13331-cit-0037","doi-asserted-by":"crossref","first-page":"22725","DOI":"10.1074\/jbc.R110.125294","article-title":"Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target","volume":"285","author":"Raney","year":"2010","journal-title":"J Biol Chem"},{"key":"2024103012371917600_jphp13331-cit-0038","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-809712-0.00014-9","article-title":"Delicate dance in treating hepatitis C infections and overcoming resistance","volume-title":"The Viral Proteases and Their Inhibitors","author":"Parasrampuria","year":"2017","edition":"1st edn"},{"key":"2024103012371917600_jphp13331-cit-0039","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1021\/jm300021v","article-title":"Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline","volume":"55","author":"Li","year":"2012","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0040","doi-asserted-by":"crossref","first-page":"e0148181","DOI":"10.1371\/journal.pone.0148181","article-title":"Discovery of novel hepatitis C Virus NS5B polymerase inhibitors by combining random forest, multiple e-pharmacophore modeling and docking","volume":"11","author":"Wei","year":"2016","journal-title":"PLoS One"},{"key":"2024103012371917600_jphp13331-cit-0041","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.bmc.2011.11.061","article-title":"Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase","volume":"20","author":"Manfroni","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0042","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bmcl.2011.11.091","article-title":"Novel substituted pyrimidines as HCV replication (replicase) inhibitors","volume":"22","author":"Kwong","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012371917600_jphp13331-cit-0043","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1016\/j.bmcl.2012.03.036","article-title":"5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors","volume":"22","author":"Arasappan","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012371917600_jphp13331-cit-0044","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1016\/j.bmcl.2012.06.099","article-title":"Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors","volume":"22","author":"Girijavallabhan","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012371917600_jphp13331-cit-0045","article-title":"HCV Replicon Systems","volume-title":"The Hepatitis C VIRUSES: Genomes and Molecular Biology","author":"Blight","year":"2006"},{"key":"2024103012371917600_jphp13331-cit-0046","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1039\/C5CC10594C","article-title":"The discovery and characterization of a novel scaffold as a potent hepatitis C virus inhibitor","volume":"52","author":"Liu","year":"2016","journal-title":"Chem Commun"},{"key":"2024103012371917600_jphp13331-cit-0047","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ardp.201500365","article-title":"Synthesis and biological evaluation of 2-aminobenzothiazole and benzimidazole analogs based on the clathrodin structure","volume":"349","author":"Montalv\u00e3o","year":"2016","journal-title":"Arch Pharm Chem Life Sci"},{"key":"2024103012371917600_jphp13331-cit-0048","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1021\/jm801240d","article-title":"Structure-Activity Relationship of new anti-hepatitis C virus agents: heterobicycle\u2212coumarin conjugates","volume":"52","author":"Neyts","year":"2009","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0049","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.antiviral.2013.08.009","article-title":"Anti-hepatitis C virus RdRp activity and replication of novel anilinobenzothiazole derivatives","volume":"100","author":"Peng","year":"2013","journal-title":"Antivir Res"},{"key":"2024103012371917600_jphp13331-cit-0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP2533","article-title":"Selective anti-herpesvirus agents","volume":"23","author":"De Clercq","year":"2013","journal-title":"Antivir Chem Chemother"},{"key":"2024103012371917600_jphp13331-cit-0051","first-page":"848","article-title":"Synthesis of certain pyrimido[2,1-b]benzothiazole and benzothiazolo[2,3-b]quinazoline derivatives for in vitro antitumor and antiviral activities","volume":"50","author":"El-Sherbeny","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"2024103012371917600_jphp13331-cit-0052","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ardp.200900195","article-title":"Stereoselective synthesis and antiviral activity of (1E,2Z,3E)-1-(piperidin-1-yl)-1-(arylhydrazono)-2-[(benzoyl\/benzothiazol-2-oyl)hydrazono]-4-(aryl(1))but-3-enes","volume":"343","author":"Abdel-Aziza","year":"2010","journal-title":"Arch Pharm"},{"key":"2024103012371917600_jphp13331-cit-0053","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1128\/iai.15.1.145-148.1977","article-title":"Frentizole, a novel immunosuppressive, and azathioprine: their comparative effects on host resistance to Pseudomonas aeruginosa, Candida albicans, Herpes Simplex virus, and influenza (Ann Arbor) virus","volume":"15","author":"Scheetz","year":"1977","journal-title":"Infect Immun"},{"key":"2024103012371917600_jphp13331-cit-0054","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0055","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2336","article-title":"HIV drug development: the next 25 years","volume":"6","author":"Flexner","year":"2007","journal-title":"Nat Rev Drug Dis"},{"key":"2024103012371917600_jphp13331-cit-0056","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"2024103012371917600_jphp13331-cit-0057","first-page":"328","article-title":"Novel drug targets in 2018","volume":"18","author":"Ursu","year":"2019","journal-title":"Nat Rev Drug Dis"},{"key":"2024103012371917600_jphp13331-cit-0058","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/092986706775476089","article-title":"HIV-1 reverse transcriptase: a therapeutical target in the spotlight","volume":"13","author":"Castro","year":"2006","journal-title":"Curr Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0059","first-page":"266","article-title":"Synthesis and HIV-1 reverse transcriptase inhibitor activity of some 2, 5, 6-substituted benzoxazole, benzimidazole, benzothiazole and oxazolo (4, 5-b) pyridine derivatives","volume":"53","author":"Akbay","year":"2003","journal-title":"Arzneim Forsch Drug Res"},{"key":"2024103012371917600_jphp13331-cit-0060","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/acs.jmedchem.5b01357","article-title":"A parallel synthesis approach to the identification of novel diheteroarylamide-based compounds blocking HIV replication: potential inhibitors of HIV-1 pre-mRNA alternative splicing","volume":"59","author":"Cheung","year":"2016","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0061","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1093\/nar\/gkw1223","article-title":"Modulation of the splicing regulatory function of srsf10 by a novel compound that impairs HIV-1 replication","volume":"45","author":"Shkreta","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2024103012371917600_jphp13331-cit-0062","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0063","first-page":"169","article-title":"Development of protease inhibitors and the fight with drug-resistant HIV-1 variants","volume-title":"HIV-1: Molecular biology and pathogenesis: clinical application","author":"Mitsuya","year":"2007"},{"key":"2024103012371917600_jphp13331-cit-0064","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"Int J Pharm"},{"key":"2024103012371917600_jphp13331-cit-0065","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1016\/j.bmc.2007.09.010","article-title":"Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV","volume":"15","author":"Ghosh","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0066","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1021\/acs.jmedchem.7b00172","article-title":"Design and development of highly potent hiv-1 protease inhibitors with a crown-like oxotricyclic core as the P2-ligand to combat multidrug-resistant HIV variants","volume":"60","author":"Ghosh","year":"2017","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0067","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/acs.jmedchem.8b00298","article-title":"Design and synthesis of highly potent HIV-1 protease inhibitors containing tricyclic fused ring systems as novel P2 ligands: structure-activity studies, biological and x-ray structural analysis","volume":"61","author":"Ghosh","year":"2018","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0068","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1021\/jm049454n","article-title":"Design of HIV-1 protease inhibitors active on multidrug-resistant virus","volume":"48","author":"Surleraux","year":"2005","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0069","doi-asserted-by":"crossref","first-page":"11961","DOI":"10.1128\/JVI.00967-10","article-title":"In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors","volume":"84","author":"Koh","year":"2010","journal-title":"J Vir"},{"key":"2024103012371917600_jphp13331-cit-0070","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00372-19","article-title":"Novel protease inhibitors containing c-5-modified bis-tetrahydrofuranylurethane and aminobenzothiazole as P2 and P2' ligands that exert potent antiviral activity against highly multidrug-resistant HIV-1 with a high genetic barrier against the emergence of drug resistance","volume":"63","author":"Takamatsu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012371917600_jphp13331-cit-0071","doi-asserted-by":"crossref","first-page":"7699","DOI":"10.1021\/jm1008743","article-title":"Structure-based design, synthesis and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones","volume":"53","author":"Ali","year":"2010","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0072","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1016\/j.bmcl.2012.06.022","article-title":"Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors","volume":"22","author":"Jonckers","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012371917600_jphp13331-cit-0073","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1021\/jm5008352","article-title":"An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases","volume":"57","author":"Ung","year":"2014","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0074","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitors to treat HIV\/AIDS","volume":"4","author":"Pommier","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012371917600_jphp13331-cit-0075","first-page":"36","article-title":"HIV pharmacotherapy: a review of integrase inhibitors","volume":"29","author":"Wong","year":"2016","journal-title":"J Am Acad PAs"},{"key":"2024103012371917600_jphp13331-cit-0076","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1016\/j.febslet.2014.08.004","article-title":"Discovery of a novel HIV-1 integrase inhibitor from natural compounds through structure based virtual screening and cell imaging","volume":"588","author":"Gu","year":"2014","journal-title":"FEBS Lett"},{"key":"2024103012371917600_jphp13331-cit-0077","first-page":"1493","article-title":"Synthesis and antimicrobial activity of pyrazolinone and pyrazole analogues containing quinoline moiety","volume":"52B","author":"Amir","year":"2013","journal-title":"Ind J Chem"},{"key":"2024103012371917600_jphp13331-cit-0078","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1016\/S0968-0896(03)00493-0","article-title":"Synthesis and biological evaluation of benzo[d]isothiazole, benzothiazole and thiazole Schiff bases","volume":"11","author":"Vicini","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0079","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.bmcl.2011.03.105","article-title":"Synthesis and in vitro anti-HIV activity of N-1,3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamide derivatives using MTT method","volume":"21","author":"Bhavsar","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012371917600_jphp13331-cit-0080","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00044-015-1358-0","article-title":"Synthesis of some new 2-amino-6-thiocyanato benzothiazole derivatives bearing 2,4-thiazolidinediones and screening of their in vitro antimicrobial, antitubercular and antiviral activities","volume":"24","author":"Shaikh","year":"2015","journal-title":"Med Chem Res"},{"key":"2024103012371917600_jphp13331-cit-0081","first-page":"5469","article-title":"A novel small-molecule inhibitor of HIV-1 entry","volume":"9","author":"Heredia","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2024103012371917600_jphp13331-cit-0082","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1128\/AAC.00299-11","article-title":"Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system","volume":"55","author":"Urano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012371917600_jphp13331-cit-0083","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bmcl.2015.11.036","article-title":"Synthesis of the biotinylated anti-HIV compound BMMP and the target identification study","volume":"26","author":"Kamo","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012371917600_jphp13331-cit-0084","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1021\/jm701585h","article-title":"Structure-activity relationship study on anti-HIV 6-desfluoroquinolones","volume":"51","author":"Tabarrini","year":"2008","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1021\/jm901211d","article-title":"A 1,8-naphthyridone derivative targets the hiv-1 tat-mediated transcription and potently inhibits the HIV-1 replication","volume":"53","author":"Massari","year":"2010","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0086","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4155\/fmc.10.208","article-title":"6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. 6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors","volume":"2","author":"Tabarrini","year":"2010","journal-title":"Fut Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0087","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.talanta.2011.06.047","article-title":"Synthesis and chromatographic enantioresolution of anti-HIV quinolone derivatives","volume":"85","author":"Natalini","year":"2011","journal-title":"Talanta"},{"key":"2024103012371917600_jphp13331-cit-0088","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nsmb.1779","article-title":"Structures of influenza A proteins and insights into antiviral drug targets","volume":"17","author":"Das","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"2024103012371917600_jphp13331-cit-0089","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/jm00306a011","article-title":"Heterocyclic substituted ureas. II. Immunosuppressive and antiviral activity of benzothiazole- and benzoxazoleureas","volume":"12","author":"Charles","year":"1969","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0090","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1021\/jm00299a062","article-title":"Studies on the in vivo antiviral effects of benzothiazole derivatives against various influenza A2 strains","volume":"13","author":"Akerfeldt","year":"1970","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0091","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","article-title":"Immune signaling by RIG-I-like receptors","volume":"34","author":"Loo","year":"2011","journal-title":"Immunity"},{"key":"2024103012371917600_jphp13331-cit-0092","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.vaccine.2017.01.053","article-title":"A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response","volume":"35","author":"Probst","year":"2017","journal-title":"Vaccine"},{"key":"2024103012371917600_jphp13331-cit-0093","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bbrc.2014.06.077","article-title":"Inhibition of Akt kinase activity suppresses entry and replication of influenza virus","volume":"450","author":"Hirata","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"2024103012371917600_jphp13331-cit-0094","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/jm100912b","article-title":"Synthesis and biological evaluation of analogues of AKT (protein kinase B) inhibitor-IV","volume":"54","author":"Sun","year":"2011","journal-title":"J Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0095","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/cb500856c","article-title":"Anticancer\/antiviral agent Akt inhibitor-IV massively accumulates in mitochondria and potently disrupts cellular bioenergetics","volume":"10","author":"Meinig","year":"2015","journal-title":"ACS Chem Biol"},{"key":"2024103012371917600_jphp13331-cit-0096","doi-asserted-by":"crossref","first-page":"e1800225","DOI":"10.1002\/ardp.201800225","article-title":"Synthesis of novel derivatives of 7,8-dihydro-6H-imidazo[2,1-b][1,3]benzothiazol-5-one and their virus-inhibiting activity against influenza A virus","volume":"352","author":"Galochkina","year":"2019","journal-title":"Arch Pharm"},{"key":"2024103012371917600_jphp13331-cit-0097","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.3390\/v9080223","article-title":"Influenza virus infection, interferon response, viral counter-response, and apoptosis","volume":"9","author":"Shim","year":"2017","journal-title":"Viruses"},{"key":"2024103012371917600_jphp13331-cit-0098","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/v9100271","article-title":"Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins","volume":"9","author":"Bulanova","year":"2017","journal-title":"Viruses"},{"key":"2024103012371917600_jphp13331-cit-0099","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2174\/092986708786242804","article-title":"West Nile Virus NS2B\/NS3 protease as an antiviral target","volume":"15","author":"Chappell","year":"2008","journal-title":"Curr Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0100","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/AAC.01508-07","article-title":"Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen","volume":"52","author":"Mueller","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012371917600_jphp13331-cit-0101","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.antiviral.2012.02.003","article-title":"Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease","volume":"94","author":"Ezgimen","year":"2012","journal-title":"Antiviral Res"},{"key":"2024103012371917600_jphp13331-cit-0102","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cmdc.201300114","article-title":"Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 2-{6-[2-(5-phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetyl amino]benzothiazol-2-ylsulfanyl}acetamide scaffold","volume":"8","author":"Samanta","year":"2013","journal-title":"Chem Med Chem"},{"key":"2024103012371917600_jphp13331-cit-0103","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1128\/AAC.00748-11","article-title":"TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors","volume":"55","author":"Dierynck","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012371917600_jphp13331-cit-0104","volume-title":"ChemIDplus advanced: TMC-310911","author":"United States National Library of Medicine"},{"key":"2024103012371917600_jphp13331-cit-0105"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.13331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jphp.13331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jphp.13331","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/11\/1459\/60227307\/jphp13331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/11\/1459\/60227307\/jphp13331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:09:07Z","timestamp":1730297347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/72\/11\/1459\/6132643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":105,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,1]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.13331","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,11,1]]}}}